| Literature DB >> 31075724 |
Lingling Shan1, Guizhen Gao2, Weiwei Wang2, Wei Tang3, Zhantong Wang3, Zhen Yang3, Wenpei Fan3, Guizhi Zhu3, Kefeng Zhai2, Orit Jacobson3, Yunlu Dai4, Xiaoyuan Chen5.
Abstract
Nanomedicine has become a promising approach to improve cancer chemotherapy. It remains a major challenge how to enhance anti-drug efficacy and reduce side effects of anti-cancer drugs. Herein, we report a self-assembled nanoplatform (FDEP NPs) by integration of doxorubicin (DOX) and epigallocatechin-3-O-gallate (EGCG) with the help of coordination between Fe3+ ions and polyphenols. The EGCG from FDEP NPs could inhibit the expression of carbonyl reductase 1 (CBR1) protein and thereby inhibit the doxorubicinol (DOXOL) generation from DOX both in vitro and in vivo, thus the efficacy of DOX to cancerous cells is improved significantly. More importantly, the FDEP NPs could reduce cardiac toxicity and the DOX mediated toxicity to blood cells due to the repression of DOXOL production. Moreover, the blood half-life of FDEP NPs is longer than 23 h as determined by positron emission tomography (PET) imaging of biodistribution of radiolabelled NPs and HPLC measurement of plasma level of DOX, ensuring high tumor accumulation of FDEP NPs by enhanced permeability and retention (EPR) effect. The FDEP NPs also exhibited much improved antitumor effect over free drugs. Our work sheds new light on the engineering of nanomaterials for combination chemotherapy and may find unique clinical applications in the near future.Entities:
Keywords: Carbonyl reductase 1 (CBR1); Chemotherapy; Doxorubicin; Epigallocatechin-3-O-Gallate (EGCG); Polyphenols; Positron emission tomography
Mesh:
Substances:
Year: 2019 PMID: 31075724 PMCID: PMC6521851 DOI: 10.1016/j.biomaterials.2019.04.032
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479